Primary Care

Immunosuppression

Questions discussed in this category

Is it better to give dose 2 of the mRNA 2024-2025 Covid-19 vaccine at month 2 or month 6 after dose 1 in moderately immunocompromised patients?

Is there any data to suggest one time-frame is better than the other? The CDC states give "2024–2025 Dose 2 (Moderna, Novavax or Pfizer-BioNTec...

1 Answer available

What is your approach to tapering chronic steroids in patients who are at high risk of HPA suppression?

For example, patients who have been maintained on 5mg of prednisone for years without previous tapering attempts and the rheumatic disease is not acti...

1 Answer available

Would you consider a biologic or JAK inhibitor to manage active PsA in a patient on chronic antibiotic therapy if they had previously failed all conventional DMARDs (including apremilast)?

Patient is on antibiotics for chronic spinal hardware infection.

1 Answer available

How are you timing the third dose of the COVID-19 mRNA vaccine in patients on rituximab?

1 Answer available

Papers discussed in this category

Annals of the rheumatic diseases, 2018-09

Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study.

Arthritis & rheumatology (Hoboken, N.J.), 2019-02

Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis.

RMD open, 2020 Feb

Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials.

The New England journal of medicine, 2014 Jun 05

Once-weekly dalbavancin versus daily conventional therapy for skin infection.

Trials, 2022 Sep 05

Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial.

Primary Care

Immunosuppression

Questions discussed in this category

Papers discussed in this category

Related Topics in Primary Care